Tüdőrák: vizsgálatok itt: Peru

14 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  Where

  Lima

  Életkor

  18 év and over

  People

  780 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06312137 · EU 2023-508012-35-00
• 3. fázisTaking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Lima

  Életkor

  18 év and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00
• 3. fázisTaking people
  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  Where

  Lima

  Életkor

  18 év and over

  People

  675 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07190248 · EU 2024-514500-14-00
• 3. fázisTaking people
  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  Where

  Lima

  Életkor

  18 év and over

  People

  680 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06623422 · EU 2023-506327-29-00
• 3. fázisTaking people
  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Where

  Arequipa, Cusco, Lima

  Életkor

  18 év to 100 év

  People

  750 worldwide

  Run by

  Amgen

  See details and how to joinNCT05920356 · EU 2022-501863-41-00
• 3. fázisTaking people
  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  Where

  Arequipa, Lima, Surquillo

  Életkor

  18 év and over

  People

  614 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06170788 · EU 2023-503376-24-00
• 2/3. fázisTaking people
  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Where

  Arequipa, Cusco, Jesus Maria, Lima, Lima Cercado, Miraflores, San Isidro, Surquillo, Trujillo

  Életkor

  18 év and over

  People

  626 worldwide

  Run by

  Mirati Therapeutics Inc.

  See details and how to joinNCT04613596 · EU 2023-508922-83-00
• 3. fázisTaking people
  Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  Where

  Chiclayo, Lima, Trujillo

  Életkor

  18 év and over

  People

  851 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06422143 · EU 2023-510128-66-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  Where

  Lima

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06692738 · EU 2024-514281-39-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  Where

  Lima

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06627647 · EU 2024-515008-38-00
• 1/2. fázisTaking people
  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  Where

  Lima

  Életkor

  18 év and over

  People

  152 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06996782 · EU 2024-519786-22-01
• 3. fázisTaking people
  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  Where

  Lima, San Borja

  Életkor

  18 év and over

  People

  750 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07361510 · EU 2025-523586-18-00
• 3. fázisTaking people
  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  Where

  Lima Cercado, San Borja, San Isidro, Surquillo

  Életkor

  18 év and over

  People

  360 worldwide

  Run by

  Taiho Oncology, Inc.

  See details and how to joinNCT07128199 · EU 2025-521775-31-00
• No phaseTaking people
  Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

  Where

  Lima

  Életkor

  18 év and over

  People

  200 worldwide

  Run by

  Latin American Cooperative Oncology Group

  See details and how to joinNCT07192991